康众医疗(688607) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 was ¥73,660,695.36, a decrease of 30.55% compared to the same period last year[5] - Net profit attributable to shareholders for Q3 2021 was ¥17,119,345.75, down 34.55% year-on-year[5] - The net profit excluding non-recurring gains and losses for Q3 2021 was ¥12,789,204.13, a decline of 43.51% compared to the previous year[6] - Basic and diluted earnings per share for Q3 2021 were both ¥0.19, representing a decrease of 52.70% year-on-year[6] - Total revenue for the first three quarters of 2021 reached ¥250,934,141.22, an increase of 9.06% compared to ¥228,879,089.29 in the same period of 2020[21] - Operating profit for the third quarter was ¥77,386,519.29, up from ¥55,940,185.68 in the previous year, reflecting a growth of 38.34%[22] - Net profit attributable to shareholders for the first three quarters was ¥63,637,165.70, compared to ¥45,946,795.57 in the same period last year, marking an increase of 38.54%[22] - Total comprehensive income for the third quarter of 2021 reached CNY 63,334,607.84, an increase from CNY 45,944,124.54 in the same period last year, representing a growth of approximately 38%[23] - Basic and diluted earnings per share for the third quarter were CNY 0.74, up from CNY 0.70 in the previous year, indicating a 5.71% increase[23] Assets and Liabilities - The company's total assets increased to ¥939,514,196.41, reflecting a growth of 117.71% compared to the end of the previous year[6] - Total assets as of the end of the third quarter amounted to ¥939,514,196.41, significantly higher than ¥431,546,055.04 at the end of the previous year[21] - Current liabilities totaled ¥81,483,752.10, an increase from ¥57,544,653.66 in the same period last year, indicating a rise of 41.49%[20] - The total liabilities of the company reached ¥89,957,930.64, compared to ¥62,703,014.06 in the same period last year, indicating an increase of 43.38%[20] - Total liabilities amounted to 62,703,014.06, a decrease of 5,261,300.78 from the previous period[29] - The company reported a non-current liability total of 5,158,360.40, down from 7,393,770.06, indicating a reduction of 2,235,409.66[29] Shareholder Information - Total number of common shareholders at the end of the reporting period is 4,700[14] - The largest shareholder, Changcheng Co., Ltd., holds 13,089,380 shares, representing 14.8% of total shares[14] - Liu Jianqiang, another major shareholder, owns 12,810,000 shares, accounting for 14.5%[14] - The company reported a total of 1,685,163 shares held by Jiangsu Qianrong Capital Management Co., Ltd., representing 1.91% of total shares[15] - The company has a significant number of shareholders with unlimited sale conditions, including major investment funds[15] - The company is under the control of Liu Jianqiang and Gao Peng, who hold 46.10% and 41.64% of the shares in a related entity, respectively[15] - The company has not disclosed any other significant relationships or agreements among shareholders[15] Cash Flow and Investments - Cash flow from operating activities for the year-to-date period decreased by 65.06% to ¥16,308,165.89[12] - Cash inflows from operating activities totaled CNY 301,156,278.34, compared to CNY 261,374,753.26 in the prior year, reflecting a year-over-year increase of about 15.2%[25] - Net cash flow from operating activities was CNY 16,308,165.89, a decrease from CNY 46,678,774.18 in the same period last year, showing a decline of approximately 65%[25] - Cash inflows from investment activities were CNY 954,857,099.78, significantly higher than CNY 511,959,568.62 in the previous year, indicating an increase of approximately 86.5%[26] - Net cash flow from financing activities was CNY 445,262,473.91, a turnaround from a net outflow of CNY 34,534,283.95 in the same period last year[26] - The company received CNY 447,342,486.13 from investment, marking a substantial increase compared to the previous year[26] - The company reported a significant increase in cash received from tax refunds, amounting to CNY 13,451,932.29, compared to CNY 4,765,570.32 in the previous year, representing an increase of approximately 182%[25] Research and Development - Research and development expenses for Q3 2021 amounted to ¥8,191,092.36, an increase of 28.86% year-on-year, accounting for 11.12% of revenue[6] - Research and development expenses for the first three quarters were ¥21,199,544.39, up from ¥17,320,823.11 in the same period last year, reflecting a growth of 22.06%[21] Equity - The company reported a significant increase in total equity attributable to shareholders, which rose by 130.35% year-on-year[12] - The equity attributable to shareholders increased to ¥849,545,856.51 from ¥368,803,960.89, representing a growth of 130.00%[20] - Total equity attributable to shareholders reached 368,803,960.89, remaining unchanged from the previous period[29]